Navigation Links
Metabolic syndrome increases risk of both major types of primary liver cancer
Date:7/21/2011

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

According to data from the National Cancer Institute, 24,120 new cases of liver and intrahepatic bile duct cancer and close to 19,000 deaths from the diseases occurred in the U.S. in 2010. Major risk factors for HCC, the most common type of liver cancer, are chronic infection with hepatitis B and C viruses and excessive alcohol consumption. ICC, the second most common type of liver cancer, is associated with primary sclerosing cholangitis and inflammatory bowel disease. However, the cause of up to half of HCC and ICC remains unknown.

"There has been an increase in the incidence rates of liver cancerHCC and ICCin the U.S.," explains lead author Tania Welzel, M.D., with the National Cancer Institute and Klinikum der J.W. Goethe-Universitt. "While metabolic syndrome is a recognized risk factor for HCC and may also modify ICC risk, the magnitude of this effect has not been investigated on a large scale in the U.S." Metabolic syndrome comprises a group of medical conditions which include central obesity (excess abdominal-area weight), raised fasting glucose levels and diabetes mellitus, raised triglycerides, reduced HDL cholesterol, and hypertension.

For the present study, Dr. Welzel and colleagues examined the association between metabolic syndrome and development of primary liver cancers in the general U.S. population. Using the SEER-Medicare database, researchers identified individuals diagnosed with HCC or ICC between 1993 and 2005. A 5% sample of individuals residing in geographic regions similar to SEER registries was selected for comparison purposes. A total of 364
'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related biology news :

1. Key metabolic pathway implicated in intractable form of breast cancer
2. Hold your breath: Air pollution plays role in cardiac, metabolic diseases
3. Study shows pine bark naturally improves kidney function in patients with metabolic syndrome
4. Metabolic cost of human sleep deprivation quantified by University of Colorado team
5. Birch bark ingredient comes with many metabolic benefits
6. Seaweed as biofuel? Metabolic engineering makes it a viable option
7. Longevity breakthrough: The metabolic state of mitochondria controls life span
8. Study finds low vitamin-d levels in northern California residents with metabolic syndrome
9. AgriLife scientist: Functional amino acids regulate key metabolic pathways
10. Imaging reveals key metabolic factors of cannibalistic bacteria
11. Native-like spider silk produced in metabolically engineered bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... The Brain-Computer Interface (BCI) research team at Singapore,s ... the worldwide BCI Competition IV, 2008, in all ... The results were announced on Dec. 12 ... conference in Vancouver, Canada. The Singapore scientists ...
... COLD SPRING HARBOR, N.Y. (Dec. 18, 2008) ... . They build, process, activate, and inactivate; they polymerize, ... shorten, signal, cleave, inhibit, digest, fluoresce, induce, excise, carry, ... and perform countless more activities." This excerpt is ...
... of pregnancy is clearly linked with an increased risk of cleft ... cigarette smoke do not appear to be involved. This is shown ... Oral clefts are one of the most common birth ... followed by closure of the palate at week 9. If this ...
Cached Biology News:Singapore research team first place in Brain-Computer Interface contest 2New manual presents robust, state-of-the-art proteomics methods for teaching and research 2First trimester smoking linked to oral clefts 2
(Date:8/26/2015)... ... 26, 2015 , ... MediVet Biologics, a leader in Veterinary ... to open in Manhattan, Kansas in early October, 2015. The location of the ... and development through collaboration with researchers from Kansas State University’s College of Veterinary ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. ... Wis. The company has added a AS16 Sharples centrifuge to harvest products after ... bacterial or fungal fermentation process development. , The new centrifuge greatly expands ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... CRTX ), a specialty pharmaceutical company focused on acquiring, developing and ... for the year ended December 31, 2008. Highlights: , ... Net Revenues more than doubled to $64.9 Million, an increase of 131% ... , Income from Operations increased to ...
... natural skin care product called Ambra-Lift™ by Elina™ Organics ... a substance found in the skin of grapes and red wine, has ... Resveratrol. , ... Kalamazoo, MI (PRWEB) March 26, 2009 -- A recent ...
... 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... outsourcing company serving the,pharmaceutical, biotechnology, and medical device ... today announced its financial results for,fourth-quarter and full-year ... ), Highlights, ...
Cached Biology Technology:Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 3Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 4Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 5Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 6Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 7Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 8Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 9Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 10Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 11Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 12Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20